INmune Bio plunges as Alzheimer's drug misses mid-stage trial goal

Inmune Bio

30/06/2025 12:56

** Shares of drug developer INmune Bio INMB.O fall 60% to $2.09 premarket

** Co's experimental Alzheimer's drug, XPro, did not meet the main goal of improving cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage trial

** XPro is designed to target and inhibit inflammatory signals associated with a type of protein called tumor necrosis factor without suppressing the immune system

** Co plans to file for FDA breakthrough therapy designation and schedule an End-of-Phase 2 meeting with the health regulator in Q4 2025

** As of last close, stock up 14% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))